Published in J Urol on March 04, 2008
Effect of age, tumor risk, and comorbidity on competing risks for survival in a U.S. population-based cohort of men with prostate cancer. Ann Intern Med (2013) 3.74
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Comorbidities, treatment and ensuing survival in men with prostate cancer. J Gen Intern Med (2011) 1.69
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology (2009) 1.49
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality. Cancer Prev Res (Phila) (2011) 1.17
Impact of surgical margin status on prostate-cancer-specific mortality. BJU Int (2012) 1.13
The need for, and utilization of prostate-bed radiotherapy after radical prostatectomy for patients with prostate cancer in British Columbia. Can Urol Assoc J (2012) 1.07
Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer (2011) 1.04
Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagn Pathol (2012) 1.00
Risk-stratified survival rates and predictors of biochemical recurrence after radical prostatectomy in a Nara, Japan, cohort study. Int J Clin Oncol (2011) 0.97
Prognostic determinants in prostate cancer. Cancer J (2011) 0.95
Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy. Int J Clin Oncol (2014) 0.83
Multiple cores of Gleason score 6 correlate with favourable findings at radical prostatectomy. BJU Int (2013) 0.82
Oncologic outcome after radical prostatectomy in men with PSA values above 20 ng/ml: a monocentric experience. World J Urol (2009) 0.82
Concurrent chemoradiation for high-risk prostate cancer. World J Clin Oncol (2015) 0.81
Oncologic outcomes following radical prostatectomy in the active surveillance era. Can Urol Assoc J (2013) 0.77
Prediction of long-term other-cause mortality in men with early-stage prostate cancer: results from the Prostate Cancer Outcomes Study. Urology (2014) 0.76
Radical Prostatectomy as a First-Line Treatment in Patients with Initial PSA >20 ng/mL. Int J Surg Oncol (2012) 0.75
Changes in Susceptibility to Oncolytic Vesicular Stomatitis Virus during Progression of Prostate Cancer. J Virol (2015) 0.75
The long-term outcomes after radical prostatectomy of patients with pathologic Gleason 8-10 disease. Adv Urol (2011) 0.75
Risk stratification and early oncologic outcomes following robotic prostatectomy. JSLS (2010) 0.75
External beam radiotherapy for localized prostate cancer. Asian J Androl (2015) 0.75
Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer. Curr Urol (2016) 0.75
Do tumor volume, percent tumor volume predict biochemical recurrence after radical prostatectomy? A meta-analysis. Int J Clin Exp Med (2015) 0.75
First danish single-institution experience with radical prostatectomy: biochemical outcome in 1200 consecutive patients. Prostate Cancer (2010) 0.75
Validation of revised Epstein's criteria for insignificant prostate cancer prediction in a Greek subpopulation. Hippokratia (2015) 0.75
Perineural invasion is an independent predictor of biochemical recurrence of prostate cancer after local treatment: a meta-analysis. Int J Clin Exp Med (2015) 0.75
Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population. J Cancer Res Clin Oncol (2017) 0.75
Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics. World J Urol (2014) 0.75
Surgical method influences specimen margins and biochemical recurrence during radical prostatectomy for high-risk prostate cancer: a systematic review and meta-analysis. World J Urol (2017) 0.75
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res (2006) 8.21
Radical nephrectomy for pT1a renal masses may be associated with decreased overall survival compared with partial nephrectomy. J Urol (2008) 5.30
Comparison of 1,800 laparoscopic and open partial nephrectomies for single renal tumors. J Urol (2007) 5.24
Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci U S A (2004) 5.13
The etiology and incidence of anaphylaxis in Rochester, Minnesota: a report from the Rochester Epidemiology Project. J Allergy Clin Immunol (2008) 4.10
Pelvic lymph node dissection in prostate cancer. Eur Urol (2009) 3.93
Every minute counts when the renal hilum is clamped during partial nephrectomy. Eur Urol (2010) 3.71
Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol (2003) 3.66
Solid renal tumors: an analysis of pathological features related to tumor size. J Urol (2003) 3.48
Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease. J Am Soc Nephrol (2010) 3.47
Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer (2003) 3.33
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res (2007) 3.23
Urachal carcinoma: clinicopathologic features and long-term outcomes of an aggressive malignancy. Cancer (2006) 3.08
The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol (2010) 3.08
Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol (2010) 3.06
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. World J Surg (2002) 2.68
Robotic-assisted laparoscopic partial nephrectomy: technique and initial clinical experience with DaVinci robotic system. Urology (2004) 2.68
Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol (2011) 2.63
Sarcomatoid renal cell carcinoma: an examination of underlying histologic subtype and an analysis of associations with patient outcome. Am J Surg Pathol (2004) 2.61
The impact of positive surgical margins on mortality following radical prostatectomy during the prostate specific antigen era. J Urol (2010) 2.60
Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer (2011) 2.58
Two common chromosome 8q24 variants are associated with increased risk for prostate cancer. Cancer Res (2007) 2.56
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation. Kidney Int (2010) 2.51
Treatment of patients with small renal masses: a survey of the American Urological Association. J Urol (2010) 2.45
The impact of temporal presentation on clinical and pathological outcomes for patients with sporadic bilateral renal masses. Eur Urol (2008) 2.40
Comparison of warm ischemia versus no ischemia during partial nephrectomy on a solitary kidney. Eur Urol (2010) 2.38
Radiation therapy after radical prostatectomy: impact on metastasis and survival. J Urol (2009) 2.37
The impact of ischemia time during open nephron sparing surgery on solitary kidneys: a multi-institutional study. J Urol (2007) 2.36
Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol (2011) 2.33
Comparison of microsatellites versus single-nucleotide polymorphisms in a genome linkage screen for prostate cancer-susceptibility Loci. Am J Hum Genet (2004) 2.31
Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. PLoS One (2013) 2.31
Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. Eur Urol (2011) 2.29
Shock wave lithotripsy and diabetes mellitus: a population-based cohort study. Urology (2011) 2.26
B7-H4 expression in renal cell carcinoma and tumor vasculature: associations with cancer progression and survival. Proc Natl Acad Sci U S A (2006) 2.24
Kidney stones and the risk for chronic kidney disease. Clin J Am Soc Nephrol (2009) 2.22
The effect of benign lower urinary tract symptoms on subsequent prostate cancer testing and diagnosis. Eur Urol (2013) 2.19
B7-H3 ligand expression by prostate cancer: a novel marker of prognosis and potential target for therapy. Cancer Res (2007) 2.19
Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. Urology (2013) 2.16
Perceptions of Active Surveillance and Treatment Recommendations for Low-risk Prostate Cancer: Results from a National Survey of Radiation Oncologists and Urologists. Med Care (2014) 2.14
Reassessing the diagnostic yield of saturation biopsy of the prostate. Eur Urol (2007) 2.12
A critical analysis of the long-term impact of radical prostatectomy on cancer control and function outcomes. Eur Urol (2011) 2.11
Complications of contemporary open nephron sparing surgery: a single institution experience. J Urol (2005) 2.10
A tissue biomarker panel predicting systemic progression after PSA recurrence post-definitive prostate cancer therapy. PLoS One (2008) 2.09
Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. J Urol (2013) 2.07
Partial versus radical nephrectomy for 4 to 7 cm renal cortical tumors. J Urol (2009) 2.05
Significance of distal ureteral margin at radical cystectomy for urothelial carcinoma. J Urol (2010) 2.05
Urinary fistulas following external radiation or permanent brachytherapy for the treatment of prostate cancer. J Urol (2005) 2.01
PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer (2007) 2.00
The relationship of the intensity of posttreatment prostate-specific antigen surveillance and prostate cancer outcomes: results from a population-based cohort. Mayo Clin Proc (2012) 2.00
Development and evaluation of BioScore: a biomarker panel to enhance prognostic algorithms for clear cell renal cell carcinoma. Cancer (2009) 2.00
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int (2005) 2.00
Tumor cell and tumor vasculature expression of B7-H3 predict survival in clear cell renal cell carcinoma. Clin Cancer Res (2008) 1.97
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet (2003) 1.96
Outcome of stage T2 or greater renal cell cancer treated with partial nephrectomy. J Urol (2010) 1.93
Surgical treatment of renal cell carcinoma in the immunocompromised transplant patient. Urology (2009) 1.92
Prevalence of renal artery and kidney abnormalities by computed tomography among healthy adults. Clin J Am Soc Nephrol (2010) 1.91
Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol (2010) 1.89
Clinical characteristics of potential kidney donors with asymptomatic kidney stones. Nephrol Dial Transplant (2011) 1.87
Phenotypic characterization of kidney stone formers by endoscopic and histological quantification of intrarenal calcification. Kidney Int (2013) 1.84
Positive surgical margins at partial nephrectomy: predictors and oncological outcomes. J Urol (2008) 1.83
Comparison of standardized and nonstandardized nuclear grade of renal cell carcinoma to predict outcome among 2,042 patients. Am J Clin Pathol (2002) 1.82
Charlson co-morbidity index as a predictor of outcome after surgery for renal cell carcinoma with renal vein, vena cava or right atrium extension. J Urol (2003) 1.81
A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. J Urol (2005) 1.80
Survival after complete surgical resection of multiple metastases from renal cell carcinoma. Cancer (2011) 1.80
Phenotypic and functional analysis of human SLC26A6 variants in patients with familial hyperoxaluria and calcium oxalate nephrolithiasis. Am J Kidney Dis (2008) 1.77
Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates. Eur Urol (2010) 1.76
Endoscopic management of upper tract transitional cell carcinoma in patients with normal contralateral kidneys. Urology (2008) 1.76
Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Clin J Am Soc Nephrol (2006) 1.75
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol (2008) 1.73
Outcomes following partial nephrectomy by tumor size. J Urol (2008) 1.72
Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. Cancer (2005) 1.71
Administrative data sets are inaccurate for assessing functional outcomes after radical prostatectomy. J Urol (2011) 1.69
Long-term complications of conduit urinary diversion. J Urol (2010) 1.66
Radical prostatectomy for prostatic adenocarcinoma: a matched comparison of open retropubic and robot-assisted techniques. BJU Int (2008) 1.64
Hypermethylation of genes for diagnosis and risk stratification of prostate cancer. Cancer Invest (2009) 1.64
Fat malabsorption and increased intestinal oxalate absorption are common after Roux-en-Y gastric bypass surgery. Surgery (2011) 1.64
The long-term clinical impact of biochemical recurrence of prostate cancer 5 or more years after radical prostatectomy. J Urol (2003) 1.64